Safety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation Trial

Authors: Mark R. Barakat, MD, David Brown, MD, Allen Hu, MD, Rahul N. Khurana, MD, Dennis Marcus, MD, Joel Pearlman, MD, PhD, Charles C. Wykoff, MD, PhD, Barry Kapik, MS, Thomas Ciulla, MD, MBA

Source: Ophthalmology Science, Vol 5, Iss 1, Pp 100586- (2025)

Subject Terms: Age-related macular degeneration, AMD, Axitinib, Suprachoroidal, Tyrosine kinase inhibitor, Ophthalmology, RE1-994

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666914524001222; https://doaj.org/toc/2666-9145

Access URL: https://doaj.org/article/ff6174f6c3444b01bcdabdb6dcbdd020